Skip to main content

View full-text article in PMC

. 2021 Apr 20;64(7):1461–1479. doi: 10.1007/s00125-021-05442-2

Table 2.

FXR agonists and FGF-19 analogues that target hepatic lipid and glucose metabolism

Drug	Mechanism of action	Mode of administration	Regulatory status	Clinical effect					References
Drug	Mechanism of action	Mode of administration	Regulatory status	Steatosis	Fibrosis markers	Hepatic enzymes	HbA_1c	Insulin resistance	References
Obeticholic acid (INT-747)	FXR agonist	PO	Phase III	↓, mild	↓	↓	=	NA	[34–36]
Cilofexor (GS-9674)	FXR agonist	PO	Phase II	↓	=	↓	NA	NA	[165, 166]
Nidufexor (LMB763)	Non-bile acid FXR agonist	PO	Phase II	↓	↓	↓	=	=	[44, 167]
Tropifexor (LNJ452)	Non-bile acid FXR agonist	PO	Phase IIb	↓	↓	↓	NA	NA	[41, 42]
EDP-305	Non-bile acid FXR agonist	PO	Phase II	↓^a	↓^a	↓^a	NA	NA	[43, 168] ^a
Aldafermin (NGM282)	FGF-19 analogue	SC	Phase II	↓	↓	↓	=	=	[38–40, 169–171]

^aPreclinical data

PO, oral; SC, subcutaneous injection